Yin, Hao Park, Soo-Young Wang, Xiao-Jun Misawa, Ryosuke J. Grossman, Eric Tao, Jing Zhong, Rong Witkowski, Piotr I. Bell, Graeme Chong, Anita S. Effect of pioglitazone on endogenous beta-cell regeneration in MIP-luc mice. <p>(a) Overview of experimental design. Following treatment with STZ, diabetic MIP-luc mice (BG >400 mg/dl) received an insulin implant at week 0, 4 and 8 post-STZ (grey arrows). Mice were divided into two groups at 6 weeks post-STZ, receiving CMC (No Rx) or Pio (25 mg/kg; 5X/week; Pio). BG (b) and the bioluminescent signal from the endogenous beta-cells (c) were monitored every week. Data are presented as mean (N = 5/group) ± standard error of mean (SEM). (d) Bioluminescent signal at week 12 post-STZ in control (No Rx) or Pio-treated groups as a mean percentage of bioluminescence prior to STZ treatment.</p> developmental biology;Organism development;regeneration;immunology;Immunologic subspecialties;transplantation;Model organisms;Animal models;mouse;Clinical immunology;Immune response;immunomodulation;Drugs and devices;Clinical pharmacology;Endocrinology;Diabetic endocrinology;Diabetes mellitus type 1;Diabetes mellitus type 2;surgery;Transplant surgery;pioglitazone;endogenous;beta-cell;mip-luc 2013-06-06
    https://plos.figshare.com/articles/figure/_Effect_of_pioglitazone_on_endogenous_beta_cell_regeneration_in_MIP_luc_mice_/713054
10.1371/journal.pone.0065777.g002